Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.56 |
| ▸ | DHODH | Q02127 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289752 | 0.86 | SCN9A (0.80) | SCN9ADHODH | |
| SCHEMBL10986022 | 0.86 | SCN9A (0.76) | SCN9AADORA2ANUDT1 | |
| SCHEMBL24108915 | 0.80 | DHODH (0.58) | DHODHLMNA | |
| SCHEMBL13585802 | 0.80 | CYP3A4 (0.56) | SCN9ATSHR | |
| SCHEMBL16150896 | 0.78 | ADORA2A (0.60) | SCN9ALMNAADORA2A | |
| SCHEMBL29010437 | 0.78 | KMT2A (0.61) | — | |
| SCHEMBL14281527 | 0.78 | TACR3 (0.58) | LMNA | |
| SCHEMBL12749845 | 0.78 | SCN9A (0.52) | SCN9ALMNA | |
| SCHEMBL8069465 | 0.78 | SCN9A (0.81) | SCN9ALMNA | |
| SCHEMBL10990332 | 0.77 | TACR3 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| CN-112513030-A | Quinoline derivatives as tyrosine kinase inhibitors | 里格尔药品股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-4639454-A | LYMPHOID LEUKEMIA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-27 | — | — | US | disclosed |
| US-4639454-A | LYMPHOID LEUKEMIA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-27 | — | — | US | disclosed |
| US-4499094-A | PREVENTION OF RESPIRATORY, UROGENITAL, CARDIOVASCULAR AND IMMUNOLOGICAL DISORDERS WHEN USING FOR BENZDIAPINES | PHARMUKA LABORATOIRES (FR) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | SCN9A 2061/4885PDE10A 1031/4885DHODH 2963/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | SCN9A 2061/4885PDE10A 1031/4885DHODH 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.